ferric carboxymaltose(fer-ik car-box-ee-mal-tose) ,
Pregnancy Category: C
Pharmacologic: iron supplements
Pharmacologic: iron supplements
Treatment of iron deficiency anemia in adults who cannot tolerate/have an unsatisfactory response to oral iron or who have chronic kidney disease (non-dialysis dependent)
A colloidal iron complex that releases iron into circulation.
Iron replacement with improvement in indeces and symptoms of iron deficiency.
Absorption: Iron released from colloid is rapidly bioavailable.
Metabolism and Excretion: Iron is rapidly cleared from plasma and used in hemoglobin formation. Negligable renal elimination
Half-life: 7–12 hr
Time/action profile (improved indeces)
Contraindicated in: Hypersensitivity
Use Cautiously in: Geriatric: Elderly may be more sensitive to effects Obstetric: Use during pregnancy only if potential benefit justifies risk to fetus Lactation: Use cautiously Pediatric: Safe and effective use in children has not been established
Adverse Reactions/Side Effects
Central nervous system
- ↑ liver enzymes
Fluid and Electrolyte
- extravasation with skin discoloration
- hypersensitivity reactions including anaphylaxis
Drug-Drug interactionNone noted
Intravenous (Adults ≥ 50 kg) 750 mg, followed at least 7 days later by a second dose of 750 mg (total cumulative dose 1500 mg/course)
Intravenous (Adults < 50 kg) 15 mg/kg, followed at least 7 days later by a second dose of 15 mg/kg (
Iron complex for intravenous injection: 750 mg/15 ml single-use vial
- Monitor for signs and symptoms of hypersensitivity reactions (hypotension, loss of consciousness, pruritus, rash, urticaria, wheezing) for at least 30 min and stable following completion of injection.
- Monitor for injection site for extravasation. May cause long lasting brown discoloration at site. If extravasation occurs, discontinue and administer at another site.
- Monitor blood pressure during infusion. May cause transient hypertension. May cause facial flushing, dizziness and nausea. Usually resolved within 30 min following injection.
- Lab Test Considerations: Monitor hemoglobin, serum ferritin, and transferrin saturation prior to and at completion of course of therapy.
- May cause ↑ ALT.
Potential Nursing DiagnosesDeficient knowledge, related to medication regimen (Patient/Family Teaching)
- Dose is expressed in elemental iron. Each mL of ferric carboxymaltose contain 50 mg of elemental iron.
- Administer undiluted.
- Rate: Inject over 100 mg (2 mL)/min.
- Intermittent Infusion: Diluent: Dilute 750 mg of iron in not >250 mL of 0.9% NaCl. Concentration: Not <2 mg of iron/mL.Solution should be clear; avoid using solutions that contain particulate matter.
- Rate: Infuse over 15 min.
- Explain purpose of ferric carboxymaltose to patient. Ask patient if they have a history of reactions to parenteral iron products.
- Advise patient to notify health care professional if signs and symptoms of hypersensitivity reaction occurs.
- Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications. Instruct patient to avoid taking iron supplements during therapy.
- Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
- Treatment of iron deficiency anemia with improvements in hemoglobin, serum ferritin, and transferrin saturation.
Drug Guide, © 2015 Farlex and Partners